279 related articles for article (PubMed ID: 28549534)
1. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Novak JE; Alamiri K; Yee J
Am J Kidney Dis; 2018 Jan; 71(1):137-141. PubMed ID: 28549534
[TBL] [Abstract][Full Text] [Related]
2. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
3. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
[No Abstract] [Full Text] [Related]
6. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
7. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
8. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
[TBL] [Abstract][Full Text] [Related]
9. [Dabigatran specific antidote: new safety level in oral anticoagulation].
MMW Fortschr Med; 2015 Nov; 157(19):78-9. PubMed ID: 26953416
[No Abstract] [Full Text] [Related]
10. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
[TBL] [Abstract][Full Text] [Related]
12. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Giustozzi M; Verso M; Agnelli G; Becattini C
J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
[TBL] [Abstract][Full Text] [Related]
13. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B
High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
Mumoli N; Mastroiacovo D; Tamborini-Permunian E; Vitale J; Giorgi-Pierfranceschi M; Cei M; Dentali F
J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):467-477. PubMed ID: 28509761
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
16. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
18. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
19. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
Lindeman E
Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
[TBL] [Abstract][Full Text] [Related]
20. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
